

## DAFTAR PUSTAKA

1. Abu El-Asrar AM, Struyf S, Kangave D, et al. Cytokine and CXC chemokine expression patterns in aqueous humor of patients with presumed tuberculous uveitis. *Cytokine* 2012;59(2):377–81.
2. Abu El-Asrar AM, Abouammoh M, Al-Mezaine HS. Tuberculous uveitis. *Int Ophthalmol Clin* 2010;50:19–39
3. Ang M, Cheung G, Vania M, et al. Aqueous cytokine and chemokine analysis in uveitis associated with tuberculosis.
4. Ang M, Chee SP. Controversies in ocular tuberculosis. *Br J Ophthalmol* 2017;101(1):6–9.
5. Adigun R, Singh R. Tuberculosis. [Updated 2022 Jan 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK441916/>
6. Agrawal R, Rupesh Agrawal a,b,c,1 , Ilaria Testi c,1 , Andres Rousselot d , Elizabeth J. Chen. Insights into the molecular pathogenesis of ocular tuberculosis. Elsevier. Tuberculosis 2021. <https://doi.org/10.1016/j.tube.2020.102018>
7. Agarwal A, Agrawal R, Gunasekaran DV, et al. The Collaborative Ocular Tuberculosis Study (COTS)-1 Report 3: polymerase chain reaction in the diagnosis and management of tubercular uveitis: global trends. *Ocul Immunol Inflamm* 2017; 20:1–9.
8. Agrawal R, Gunasekeran DV, Grant R, et al. Clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1. *JAMA Ophthalmol* 2017;135 (12):1318–27.
9. Agarwal R, Gunasekaran DV, Agrawal A, et al. The collaborative ocular tuberculosis study (COTS)-1: a multinational description of the spectrum of choroidal involvement in 245 patients with tubercular uveitis. *Ocul Immunol Inflamm* 2018;29:1–11.
10. Agrawal R, Gunasekeran DV, Raje D, et al. Global variations and challenges with tubercular uveitis in the collaborative ocular tuberculosis study. *Invest Ophthalmol Vis Sci* 2018;59(10):4162–71.
11. Agrawal R, Gupta B, Gonzalez-Lopez JJ. The role of anti-tubercular therapy in patients with presumed ocular tuberculosis. *Ocul Immunol Inflamm* 2015;23(1): 40–6.
12. Agarwal A, Handa S, Aggarwal K, et al. The role of dexamethasone implant in the management of tubercular uveitis. *Ocul Immunol Inflamm* 2018;26(6):884–92.
13. Alli HD, Ally N, Mayet I, Dangor Z, Madhi SA. 2022. *Global prevalence and clinical outcomes of tubercular uveitis: A systematic review and meta-analysis.* *Surv Ophthalmol.* 67:770–792.

- Alvarez S, McCabe WR. Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals. *Medicine (Baltimore)* 1984;63(1):25–55.
- Amiri A, Sabooteh T, Shahsavari F. 2022. *Relationship between common polymorphisms of NRAMP1 gene and pulmonary tuberculosis in Lorestan LUR population.* medRxiv. 3:2022-05.doi: <https://doi.org/10.1101/2022.05.01.22274504>
- Alzayer Z, Al Nasser Y. Primary Lung Tuberculosis. [Updated 2022 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK567737/>
- Anggraini R, Nugraha J. NRAMP1 polymorphism and susceptibility to lung tuberculosis in Surabaya, Indonesia. *Southeast Asian J Trop Med Public Health*. 2011;42(2):338-41.
- Aravindan PP. Host genetics and tuberculosis: theory of genetic polymorphism and tuberculosis. *Lung India* 2019;36(3):244–52. [46]
- Azad AK, Sadee W, Schlesinger LS. Innate immune gene polymorphisms in tuberculosis. *Infect Immun*. 2012;80:3343
- Banerjee S, Datta R. Leishmania infection triggers hepcidin-mediated proteasomal degradation of Nramp1 to increase phagolysosomal iron availability. *Cellular Microbiology*. 2020 ; 22 : 12.
- Barton CH, Biggs TE, Baker ST, Bowen H, Atkinson PG. Nramp1: a link between intracellular iron transport and innate resistance to intracellular pathogens. *J Leukocyte Biol*. 1999; 66: 757-62.
- Basu S, Wakefield D, Biswas J, Rao NA. Pathogenesis and pathology of intraocular tuberculosis. *Ocul Immunol Inflamm* 2015;23(4):353–7.
- Basu S, Fowler BJ, Kerur N, Arnvig KB, Rao NA. NLRP3 inflammasome activation by mycobacterial ESAT-6 and dsRNA in intraocular tuberculosis. *Microb Pathog* 2018;114:219–24.
- Basu S, Elkington P, Rao NA. Pathogenesis of ocular tuberculosis : New observations and future directions. *Tuberculosis* 124. 2020 ; 1-13.
- Basu S, Rao N, Elkington P. Animal models of ocular tuberculosis: implications for diagnosis and treatment [published online ahead of print, 2020 may 14]. *Ocul Immunol Inflamm* 2020:1–7.
- Bellamy R, Ruwende C, Corrah T, McAdam KPWJ, Whittle HC, Hill AVS, 1998. Variation in the NRAMP1 gene is associated with susceptibility to tuberculosis in West Africans. *N Engl J Med* 338: 640 644
- Bennet JE, Dolin R, Blaser MJ. 2020. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease: Mycobacterium Tuberculosis. 9<sup>th</sup> ed. Philadelphia: Elsevier. pp 2985-3021
- Bhandari A, Bhandari H, Shukla R, Giri P. Phlyctenular conjunctivitis: a rare association with spinal intramedullary tuberculoma. *BMJ case reports*. 2014;2014.

- Blackwell JM, Goswami T, Carlton AWE, Dean S, Natalie P, Jacqueline KW, Susan S, E Nancy M, Christopher SP, Hiba M, and Muntaser I, 2001. SLC11A1 (Formerly NRAMP1) and disease resistance. *Cellular Microbiology*. Vol.3 Issue 12 Page 773
- Boelaert JR, Vandecasteele SJ, Appelberg R, Gordeuk VR. The effect of the host's iron status on tuberculosis. *J Infect Dis*. 2007;12:1745-53.
- Camstock GW, 1978. Tuberculosis in twins: a reanalysis of the Proffit study. *Am Rev Resp Dis*; 117:621
- Canonne-Hergaux F, Gruenheid S, Govoni G, Gros P. 1999. *The Nramp1 protein and its role in resistance to infection and macrophage function*. *Proc Assoc Am Physicians*;111(4):283–9.
- Cellier M, Gros P. The nramp family. USA: Kluwer Academic/Plenum Publishers; 2004; p.2-32.
- Cendrasari J, Kusmardi. Gen Natural Resistance-associated Macrophage Protein-1 (NRAMP1): Polimorfisme dan Hubungannya dengan Patogenesis Tuberkulosis. *Pratista Patologi*. Vol 5 No1, januari 2016
- Cheng X, Wang H. Multiple targeting motifs direct NRAMP1 into lysosomes. *Biochem Biophys Res Commun*. 2012; 419: 578-83.
- Churchyard G, Kim P, Shah NS, Rustumjee R, Gandhi N, Mathema B, Dowdy D, Kasmar A, Cardenas V. What We Know About Tuberculosis Transmission: An Overview. *J Infect Dis*. 2017 Nov 3;216(suppl\_6):S629-S635. doi: 10.1093/infdis/jix362. PMID: 29112747; PMCID: PMC5791742.
- Coppola M, Villar-Hernández R, van Meijgaarden KE, Latorre I, Muriel Moreno B, Garcia-Garcia E, Franken KLMC, Prat C, Stojanovic Z, De Souza Galvão ML, Millet JP, Sabriá J, Sánchez-Montalva A, Noguera-Julian A, Geluk A, Domínguez J, Ottenhoff THM. 2020. *Cell-Mediated Immune Responses to in vivo-Expressed and Stage-Specific Mycobacterium tuberculosis Antigens in Latent and Active Tuberculosis Across Different Age Groups*. *Front Immunol*. 11:103. doi: 10.3389/fimmu.2020.00103.
- Daley CL: The global fight against tuberculosis. *Thorac Surg Clin* 2019; 29: pp. 19
- Delgado JC, Baena A, Thim S, and Goldfeld AE, 2002. Ethnic-Specific Genetic Associations with Pulmonary Tuberculosis. *The Journal of Infectious Disease* : 186:1463-8
- Dogra M, Singh R, Agarwal A, Sharma A, Singh SR, Gautam N. dkk. 2017. *Epidemiology of uveitis in a tertiary-care referral institute in North India*. *Ocul Immunol Inflamm*. 25:S46–S53.
- El Baghdadi J, Remus N, Benslimane A, El Annaz H, Chentoufi M, Abel L, et al. Variants of the human NRAMP1 gene and susceptibility to tuberculosis in Morocco. *Int J Tuberc Lung Dis*. 2003;7(6):599-602.
- Estrada-Chavez C, Pereira-Suarez AL, Meraz MA, Arriaga C, Garcia-Carranca A, Sanchez-Rodriguez C, Mancilla R, 2001. High-level expression of NRAMP1 in peripheral blood cells and tuberculous granulomas from *Mycobacterium bovis*-infected bovines. *Infect Immun* 69:7165–7168

- Fleming MD, Trenor III CC, Su MA. 1997. *Microcytic anaemia mice have a mutation in NRAMP2, a candidate iron transporter gene*. Nat Genet; 16(4):383–6.
- Floyd K, Glaziou P, Zumla A, et al: The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respir Med 2018; 6: pp. 299-314
- Gao PS, Fujishima S, Mao XQ, Remus N, Kanda M, Enomoto T, et al, 2000. Genetic variants of NRAMP1 and active tuberculosis in Japanese populations. International Tuberculosis Genetics Team. Clin Genet 58: 74-76
- Goldman L dan Schafer AI. 2020. Goldman-Cecil Medicine: Tuberculosis. 26<sup>th</sup> ed. Philadelphia: Elsevier.
- Greenwood D, Barer M, Slack R, and Irving W. Medical Microbiology, Eighteenth Edition. 2012. Elsevier Ltd. 18, 211-225
- Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Winthrop K., ATS Mycobacterial Diseases Subcommittee. American Thoracic Society. Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416
- Gomez MA, Li S, Tremblay ML, Olivier M. NRAMP-1 expression modulates proteintyrosine phosphatase activity in macrophages: impact on host cell signaling and functions. J Biol Chem. 2007; 282: 36190-8.
- Gunasekeran DV, Gupta B, Cardoso J, Pavesio CE, Agrawal R. 2018. *Visual morbidity and ocular complications in presumed intraocular tuberculosis: An analysis of 354 cases from a non-endemic population*. Ocul Immunol Inflamm. 26:865–869.
- Gupta V, Gupta A, Rao NA. Intraocular tuberculosis—an update. Survey of ophthalmology Dec 2007;52(6):561-580
- Gupta V, Gupta A, Sachdeva N, et al: Successful management of tubercular subretinal granulomas. Ocul Immunol Inflamm 14:35--40, 2006
- Gupta A, Sharma A, Bansal R, Sharma K. Classification of intraocular tuberculosis. Ocul Immunol Inflamm 2015;23(1):7–13.
- Handayani I, Djaharuddin I, Natzir R, Arief M, Ahmad A, Hatta M, dkk. *Contribution of NRAMP1 gene expression and protein level in pulmonary and latent TB infection in Indonesia*. Journal of Applied Pharmaceutical Science. 2021 Jun 12;11(8):017-21.doi: 10.7324/JAPS.2021.110803.
- Hao X, Bai J, Ding Y, Wang J, Liu Y, Yao L, Pan W. 2020. *Characterization of antibody response against 16kD and 38kD of M. tuberculosis in the assisted diagnosis of active pulmonary tuberculosis*. Ann Transl Med, 8(15):945.
- Hatta M, Ratnawati, Tanaka M, Ito J, Shirakawa T, Kawabata M. NRAMP1/SLC11A1 gene polymorphisms and host susceptibility to Mycobacterium tuberculosis and M. leprae in South Sulawesi, Indonesia. Southeast Asian J Trop Med Public Health. 2010;41(2):386-94

- Heemskerk D, Caws M, Marais B, et al. Tuberculosis in Adults and Children. London: Springer; 2015. Chapter 2, Pathogenesis. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK344406/>
- Hsu YH, Chen CW, Sun HS, Jou R, Lee JJ, Su IJ. Association of NRAMP1 gene polymorphism with susceptibility to tuberculosis in Taiwanese aboriginals. *J Formos Med Assoc.* 2006;105(5):363-9
- Htet KKK, Liabsuetrakul T, Thein S, McNeil EB, Chongsuvivatwong V. 2018. *Improving detection of tuberculosis among household contacts of index tuberculosis patients by an integrated approach in Myanmar: a cross-sectional study.* *BMC Infect Dis*, 18(1):660.
- Hunter RL. The Pathogenesis of Tuberculosis: The Early Infiltrate of Post-primary (Adult Pulmonary) Tuberculosis: A Distinct Disease Entity. *Front Immunol.* 2018 Sep 19;9:2108. doi: 10.3389/fimmu.2018.02108. PMID: 30283448; PMCID: PMC6156532.
- Invernizzi A, Franzetti F, Viola F, Meroni L, Staurenghi G. Optic nerve head tubercular granuloma successfully treated with anti-VEGF intravitreal injections in addition to systemic therapy. *Eur J Ophthalmol* 2015;25(3):270–2.
- Jain S, Agarwal A, Gupta V. Resolution of large choroidal tuberculoma following monotherapy with intravitreal ranibizumab. *Ocul Immunol Inflamm* 2020;28(3): 494–7.
- Jain L, Panda KG, Basu S. Clinical outcomes of adjunctive sustained-release intravitreal dexamethasone implants in tuberculosis-associated multifocal serpiginoid choroiditis. *Ocul Immunol Inflamm* 2018;26(6):877–83.
- Jena B, Ludam R, Sahu M. Detection of Mycobacterium tuberculosis with conventional microscopic and culture methods. *International journal of applied research.* 2017 Dec 1. PMID: 55016965
- Jin J, Sun L, Jiao W, Zhao S, Li H, Guan X, et al. SLC11A1 (formerly NRAMP1) gene polymorphisms associated with pediatric tuberculosis in China. *Clin Infect Dis.* 2009;48(6):733-8.
- Kee AR, Gonzalez-Lopez JJ, Al-Hity A, et al. Anti tubercular therapy for intraocular tuberculosis: a systematic review and meta-analysis. *Surv Ophthalmol* 2016;61(5): 628–53.
- Kementrian Kesehatan RI. 2019. *Situasi TBC di Indonesia.* [Online]. Tersedia: <https://tbindonesia.or.id/pustaka-tbc/informasi/tentang-tbc/situasi-tbc-di-indonesia-2/>
- Kementrian Kesehatan Republik Indonesia. Pedoman Nasional Pengendalian TuberKulosis. Jakarta: Bakti Husada; 2011; hal.6
- Kim JH, Lee SY, Lee SH, Sin C, Shim JJ, In KH, et al. NRAMP1 genetic polymorphisms as a risk factor of tuberculous pleurisy. *Int J Tuberc Lung Dis.* 2003;7(4):370-5.
- Kim JH, Lee SY, Lee SH, Sin C, Shim JJ, In KH, Yoo SH, Kang KH, 2003. NRAMP1 genetic polymorphisms as a risk factor of tuberculous pleurisy. *INT J TUBERC LUNG* 7(4): 370-375

- Kon OM, Beare N, Connell D, *et al.* BTS clinical statement for the diagnosis and management of ocular tuberculosis. *BMJ Open Respiratory Research* 2022;9:e001225. doi: 10.1136/bmjresp-2022 001225
- Kumar A, Chawla R, Sharma N. 2017. Ocular tuberculosis. New Delhi: Springer.
- La Distia Nora R, Walburg KV, van Hagen PM, *et al.* Retinal pigment epithelial cells control early mycobacterium tuberculosis infection via interferon signaling. *Invest Ophthalmol Vis Sci* 2018;59(3):1384–95.
- Lee C, Agrawal R, Pavesio C. Ocular tuberculosis – a clinical conundrum. *Ocul Immunol Inflamm* 2016;24(2):237–42.
- Li HT, Zhang TT, Zhou YQ, Huang QH, Huang J. SLC11A1 (formerly NRAMP1) gene polymorphisms and tuberculosis susceptibility: a meta-analysis. *Int J Tuberc Lung Dis*. 2006;10(1):3-12.
- Liu W, Cao WC, Zhang CY, *et al.*, 2004. VDR and NRMAP1 gene polymorphisms in susceptibility to pulmonary tuberculosis among the Chinese Han population: a case-control study. *Int J Tuberc Lung Dis*; 8:428–434
- Liu W, Cao WC, Zhang CY, Tian L, Wu XM, Habbema JD, *et al.* VDR and NRAMP1 gene polymorphisms in susceptibility to pulmonary tuberculosis among the Chinese Han population: a case-control study. *Int J Tuberc Lung Dis*. 2004;8(4):428-34
- Liu, Y., Zhao, E., Zhu, L., Zhang, D., & Wang, Z. (2019). 3'UTR polymorphisms in NRAMP1 are associated with the susceptibility to pulmonary tuberculosis: A MOOSE-compliant meta-analysis. *Medicine*, 98(23), e15955. <https://doi.org/10.1097/MD.00000000000015955>
- Ludi Z, Sule AA, Samy RP, Putera I, Schrijver B, Hutchinson PE, *dkk.* 2023. *Diagnosis and biomarkers for ocular tuberculosis: From the present into the future*. *Theranostics*. 13(7):2088-2113. doi: 10.7150/thno.81488.
- Ma X, Dou S, Wright JA, Reich RA, Teeter LD, El Sahly HM, *et al.* 5' dinucleotide repeat polymorphism of NRAMP1 and susceptibility to tuberculosis among Caucasian patients in Houston, Texas. *Int J Tuberc Lung Dis*. 2002;6(9):818-23.
- Madhavan HN, Therese KL, Doraiswamy K. Further investigations on the association of Mycobacterium tuberculosis with Eales' disease. *Indian J Ophthalmol*. 2002 Mar;50(1):35-9.
- Malik S, Abel L, Tooker H, Poon A, Simkin L, Girard M, Adams GJ, Starke JR, Smith KC, Graviss EA, Musser JM, Schurr E. 2005. *Alleles of the NRAMP1 gene are risk factors for pediatric tuberculosis disease*. *Proceedings of the National Academy of Sciences*; 102(34):12183–12188.
- Marquet S, Lepage P, Hudson TJ, Musser JM, Schurr E. Complete nucleotide sequence and genomic structure of the human NRAMP1 gene region on chromosome region 2q35. *Mamm Genome*. 2000; 9: 755-62.
- McAdam AJ, Sharpe AH. Infectious diseases. In: Kumar V, Abbas AK, Fausto N, Aster JC, editors. *Robbins and Cotran: Pathologic Basic of Disease*. Philadelphia: Saunders Elsevier; 2010; p.366-371.

- McDermid JM, Prentice AM. Iron and infection: effects of host iron status and the iron-regulatory genes haptoglobin and NRAMP1 (SLC11A1) on host-pathogen interactions in tuberculosis and HIV. *Clin Sci (Lond)*. 2006;110(5):503-24
- Meilang Q, Zhang Y, Zhang J, Zhao Y, Tian C, Huang J, et al. Polymorphisms in the SLC11A1 gene and tuberculosis risk: a meta-analysis update. *Int J Tuberc Lung Dis*. 2012;16:437-46.
- Merza M, Farnia P, Anoosheh S, Varahram M, Kazampour M, Pajand O, et al. The NRAMP1, VDR and TNF-alpha gene polymorphisms in Iranian tuberculosis patients: the study on host susceptibility. *Braz J Infect Dis*. 2009;13(4):252-6.
- Moller M, Hoal EG. 2010. *Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis*. *Tuberculosis (Edinb)*; 90:71–83.
- Nayak S, Acharjya B. Mantoux test and its interpretation. *Indian Dermatol Online J*. 2012 Jan;3(1):2-6. doi: 10.4103/2229-5178.93479. PMID: 23130251; PMCID: PMC3481914.
- Nazari H, Karakousis PC, Rao NA. Replication of Mycobacterium tuberculosis in retinal pigment epithelium. *JAMA Ophthalmol* 2014;132(6):724–9.
- Neuhouser AJ, Sallam A. Ocular Tuberculosis. [Updated 2022 May 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559303/>
- Nora R et al. Tuberculosis and other causes of uveitis in Indonesia. Macmillan Publishers 2018; 32: 546-554.
- Nora, R., Walburg, K. V., van Hagen, P. M., Swagemakers, S. M. A., van der Spek, P. J., Quinten, E., van Velthoven, M., Ottenhoff, T. H. M., Dik, W. A., & Haks, M. C. (2018). Retinal Pigment Epithelial Cells Control Early Mycobacterium tuberculosis Infection via Interferon Signaling. *Investigative ophthalmology & visual science*, 59(3), 1384–1395. <https://doi.org/10.1167/iovs.17-23246>
- Nussbaum RL, McInnes RR, Willard HF, Hamosh A. Genetic variation in individuals and populations: mutation and polymorphism. In: Nussbaum RL, McInnes RR, Willard HF, Hamosh A. Thompson & Thompson Genetics in Medicine, Seventh Edition. Philadelphia: Saunders Elsevier; 2007; p.175-205.
- Parwati I, van Crevel R, Sudiro M, Alisjahbana B, Pakasi T, Kremer K, et al. Mycobacterium tuberculosis population structures differ significantly on two Indonesian Islands. *J Clin Microbiol*. 2008;46(11):3639-45.
- Putera I, La Distia Nora R, Utami N, Karuniawati A, Yasmon A, Wulandari D. dkk. 2022. *The impact of aqueous humor polymerase chain reaction and serological test results for establishing infectious uveitis diagnosis: An indonesian experience*. *Heliyon*. 8:e10988.

- Rao NA, Albin TA, Kumaradas M, Pinn ML, Fraig MM, Karakousis PC. Experimental ocular tuberculosis in Guinea pigs. *Arch Ophthalmol Chic Ill* 1960 2009;127(9):1162–6.
- Rao NA, Saraswathy S, Smith RE. Tuberculous uveitis: distribution of *Mycobacterium tuberculosis* in the retinal pigment epithelium. *Arch Ophthalmol Chic Ill* 1960 2006;124(12):1777–9.
- Ratlidge C. Iron, mycobacteria and tuberculosis. *Tuberculosis (Edinb)*. 2004;2:110-30.
- Runstadler JA, Sääla H, Savolainen A, Repo ML, Aho K, Wolf ET, et.al. Association of SLC11A1 (NRAMP1) with persistent oligoarticular and polyarticular rheumatoid factor-negative juvenile idiopathic arthritis in Finnish patients. *Arthritis Rheum*. 2005; 52: 247-56.
- Rosenbaum JT. To be or not TB? *Br J Ophthalmol* 2014;98(8):999–1000.
- Ryu S, Park YK, Bai GH, Kim SJ, Park SN, Kang S, 2000. 3'UTR polymorphisms in the NRAMP1 gene are associated with susceptibility to tuberculosis in Koreans. *Int J Tuberc Lung Dis* 4: 577 580
- Sahiratmadja E, Wieringa FT, van Crevel R, de Visser AW, Adnan I, Alisjahbana B, et al. Iron deficiency and NRAMP1 polymorphisms (INT4, D543N and 3'UTR) do not contribute to severity of anaemia in tuberculosis in the Indonesian population. *Br J Nutr*. 2007;98(4):684-90.
- Sara Gamal Gubara Mohamed<sup>1\*</sup>, Arwa Elaagip<sup>2</sup>, Maryam Atif Salaheldin<sup>1</sup>, Abeer Babiker Idris<sup>1</sup>, Taha Hussein Musa<sup>3</sup>, Fayad Osman Mohammed<sup>4</sup>, Layla Ahmed Mohammed<sup>1</sup>, Hassan Hussein Musa. Association of NRAMP1-INT4 gene with Susceptibility to Tuberculosis in the Sudanese Population: A Case-Control Study. <https://doi.org/10.1101/2021.03.15.21253579>
- Schaible UE, Kaufmann SH. Iron and microbial infection. *Nat Rev Microbiol*. 2004;2(12):946-53.
- Shakarchi FI. Ocular tuberculosis: current perspectives. *Clin Ophthalmol*. 2015 Nov 26;9:2223-7. doi: 10.2147/OPTH.S65254. PMID: 26648690; PMCID: PMC4664543.
- Sharma K, Gupta V, Bansal R, Sharma A, Sharma M, Gupta A. Novel multi-targeted polymerase chain reaction for diagnosis of presumed tubercular uveitis. *Journal of ophthalmic inflammation and infection*. 2013;3(1):25
- Sharma RK, Gupta V, Bansal R, Sharma K, Gupta A, Sachdeva N. Immune profiling of T cells infiltrating vitreous humor in tubercular uveitis. *Immunol Invest* 2018;47 (6):615–31.
- Sharma RK, Gupta A, Kamal S, et al. Role of regulatory T cells in tubercular uveitis. *Ocul Immunol Inflamm* 2018;26(1):27–36.
- Sharma RK, Sharma J, Khan ZK, et al. Diminished TLR2-TLR9 mediated CD4+ T cell responses are associated with increased inflammation in intraocular tuberculosis. *Sci Rep* 2018;8(1):13812.



- Singh N, Singh R, Sharma RK, et al. Mycobacterium tuberculosis modulates fibroblast growth factor and vascular endothelial growth factor in ocular tuberculosis [published online ahead of print, 2020 mar 11]. *Ocul Immunol Inflamm* 2020;1–7.
- Silva-Gomes S, Appelberg R, Larsen R, Soares MP, Gomes MS. 2013. *Heme catabolism by heme oxygenase-1 confers host resistance to Mycobacterium infection*. *Infect Immun*. 81(7):2536-45.
- Søborg C, Andersen AB, Madsen HO, Kok-Jensen A, Skinhøj P, Garred P. Natural resistance-associated macrophage protein 1 polymorphisms are associated with microscopypositive tuberculosis. *J Infect Dis*. 2002;186(4):517-2
- Stagas MK, Papaetis GS, Orphanidou D, Kostopoulos C, Syriou S, Reczko M, Drakoulis N. 2011. *Polymorphisms of the NRAMP1 gene: distribution and susceptibility to the development of pulmonary tuberculosis in the Greek population*. *Medical science monitor : international medical journal of experimental and clinical research*;17(1), PH1–PH6
- Takaki K, Ramakrishnan L, Basu S. A zebrafish model for ocular tuberculosis. *PloS One* 2018;13(3):e0194982.
- Tao Li a,b,1 , Longjie Wang a,b,1 , Chaofeng Guo a,b , Hongqi Zhang a,b , Peng Xu a,b , Shaohua Liu a,b , Xiaojiang Hu a,b , Qile Gao a,. Polymorphisms of SLC11A1(NRAMP1) rs17235409 associated with and susceptibility to spinal tuberculosis in a southern Han Chinese population. *Infection, Genetics and Evolution* 98 (2022) 105202. <https://doi.org/10.1016/j.meegid.2021.105202>
- Taylor GA, Feng CG, Sher A. p47 GTPases: regulators of immunity to intracellular pathogens. *Nat Rev Immunol*. 2004;2:100-9.
- Testi I, Agrawal R, Mehta S, Basu S, Nguyen Q, Pavesio C, Gupta V. Ocular tuberculosis: Where are we today?. *Indian Journal of Ophthalmology*: September 2020;68(9):1808-1817. doi: 10.4103/ijo.IJO\_1451\_20
- Thompson MJ dan Albert DM. Ocular tuberculosis. *Arch Ophthalmol*. 2005 June;123:844–849.
- Tiksnadi B, Herman H. The NRAMP1 polymorphism as a risk factor for tuberculous spondylitis. *Malaysian Orthopaedic Journal* 2013 Vol 7 No 1.
- Thayil SM, Albin TA, Nazari H, et al. Local ischemia and increased expression of vascular endothelial growth factor following ocular dissemination of Mycobacterium tuberculosis. *PloS One* 2011;6(12):e28383.
- Ulrichs ES, Kaufmann SHE, 2004. Cell-Mediated Immune response. In: *Tuberculosis*. Rom WN, Garay SM, 2nd edition. Philadelphia. Lippincott Williams & Wilkins. 251-334
- Uplekar MW, Rangan S, Weiss MG, Ogden J, Borgdorff MW, Hudelson P. 2001. *Attention to gender issues in tuberculosis control [Unresolved Issues]*. *Int J Tuberc Lung Dis*, 5(3):220–4.
- van Crevel R, Parwati I, Sahiratmadja E, Marzuki S, Ottenhoff TH, Netea MG, et al. Infection with Mycobacterium tuberculosis Beijing genotype strains is

- associated with polymorphisms in SLC11A1/NRAMP1 in Indonesian patients with tuberculosis. *J Infect Dis*. 2009;200(11):1671-4.
- Vejbaesya S, Chierakul N, Luangtrakool P, Sermduangprateep C. NRAMP1 and TNF-alpha polymorphisms and susceptibility in Thais. *Respirology*. 2007;12(2): 202-6
- Vidal SM, Malo D, Vogan K, Skamene E, Gros P. Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. *Cell*. 1993;73:469-85.
- Wang Jun, Xin-Li Zhan, Chong Liu, Dan Zhang, Lin Meng, Li Deng. MIF, TGF- $\beta$ 1, IFN- $\gamma$  and NRAMP1 gene polymorphisms in relation to the clinicopathological profile of spinal tuberculosis in Chinese Han population. *Int J Clin Exp Pathol* 2016;9(4):4438-4447
- WHO Report, 2002. Global tuberculosis control: surveillance, planning, financing, WHOC DSTB ; 295 : 21
- WHO Report, 2007. Global Tuberculosis Control.
- Wildschütz L, Ackermann D, Witten A, et al. Transcriptomic and proteomic analysis of iris tissue and aqueous humor in juvenile idiopathic arthritis-associated uveitis. *J Autoimmun* 2019;100:75–83.
- World Health Organization. Worldwide prevalence of anaemia 1993–2005. Geneva: World Health Organization; 2008. ISBN 978-92-4-159665-7.
- Wroblewski KJ, Hidayat AA, Neafie RC, Rao NA, Zapor M. Ocular tuberculosis: a clinicopathologic and molecular study. *Ophthalmology* 2011;118(4):772–7.
- Wu F, Zhang W, Zhang L, Wu J, Li C, Meng X, et al. NRAMP1, VDR, HLA-DRB1, and HLA-DQB1 gene polymorphisms in susceptibility to tuberculosis among the Chinese Kazakh population: a case-control study. *Biomed Res Int*. 2013;2013:484535.
- Yang Q, Zhang M, Chen Q, et al. Cutting edge: characterization of human tissue-resident memory T cells at different infection sites in patients with tuberculosis. *J Immunol* 2020;204(9):2331–6.
- Yanoff M dan Duker JS. *Ophthalmology: Tuberculosis, Leprosy, and Brucellosis*. 5<sup>th</sup> ed. Philadelphia: Elsevier.
- Zhang W, Shao L, Weng X, Hu Z, Jin A, Chen S, et al. Variants of the natural resistance associated macrophage protein 1 gene (NRAMP1) are associated with severe forms of pulmonary tuberculosis. *Clin Infect Dis*.
- Zhang WH, Shao L, Weng X, Hu Z, Jin A, Chen S, Pang M, and Chen ZW, 2005. Variants of the Natural Resistance-Associated Macrophage Protein1 Gene (NRAMP1) are associated with Severe Forms of Pulmonary Tuberculosis. *Clinical Infection Disease*;40:1232-1223

## LAMPIRAN HASIL SPSS

### Lampiran. Karakteristik Sampel Studi

#### *JK*

|       |           | Frequenc<br>y | Percent | Valid<br>Percent | Cumulati<br>ve<br>Percent |
|-------|-----------|---------------|---------|------------------|---------------------------|
| Valid | Laki-Laki | 49            | 59.8    | 59.8             | 59.8                      |
|       | Perempuan | 33            | 40.2    | 40.2             | 100.0                     |
|       | Total     | 82            | 100.0   | 100.0            |                           |

#### *Kelompok*

|       |         | Frequenc<br>y | Percent | Valid<br>Percent | Cumulati<br>ve<br>Percent |
|-------|---------|---------------|---------|------------------|---------------------------|
| Valid | Kasus   | 29            | 35.4    | 35.4             | 35.4                      |
|       | Kontrol | 53            | 64.6    | 64.6             | 100.0                     |
|       | Total   | 82            | 100.0   | 100.0            |                           |

#### *Kategori usia*

|       |       | Frequenc<br>y | Percent | Valid<br>Percent | Cumulati<br>ve<br>Percent |
|-------|-------|---------------|---------|------------------|---------------------------|
| Valid | 1.00  | 2             | 2.4     | 2.4              | 2.4                       |
|       | 2.00  | 30            | 36.6    | 36.6             | 39.0                      |
|       | 3.00  | 28            | 34.1    | 34.1             | 73.2                      |
|       | 4.00  | 15            | 18.3    | 18.3             | 91.5                      |
|       | 5.00  | 7             | 8.5     | 8.5              | 100.0                     |
|       | Total | 82            | 100.0   | 100.0            |                           |

### Case Processing Summary

|                          | Cases |         |         |         |       |         |
|--------------------------|-------|---------|---------|---------|-------|---------|
|                          | Valid |         | Missing |         | Total |         |
|                          | N     | Percent | N       | Percent | N     | Percent |
| Kategori usia * Kelompok | 82    | 100.0%  | 0       | 0.0%    | 82    | 100.0%  |
| JK * Kelompok            | 82    | 100.0%  | 0       | 0.0%    | 82    | 100.0%  |

### Kategori usia \* Kelompok

#### Crosstab

|               |                   |                   | Kelompok |         | Total |
|---------------|-------------------|-------------------|----------|---------|-------|
|               |                   |                   | Kasus    | Kontrol |       |
| Kategori usia | 1.00              | Count             | 2        | 0       | 2     |
|               |                   | % within Kelompok | 6.9%     | 0.0%    | 2.4%  |
|               | 2.00              | Count             | 9        | 21      | 30    |
|               |                   | % within Kelompok | 31.0%    | 39.6%   | 36.6% |
|               | 3.00              | Count             | 7        | 21      | 28    |
|               |                   | % within Kelompok | 24.1%    | 39.6%   | 34.1% |
|               | 4.00              | Count             | 6        | 9       | 15    |
|               |                   | % within Kelompok | 20.7%    | 17.0%   | 18.3% |
|               | 5.00              | Count             | 5        | 2       | 7     |
|               |                   | % within Kelompok | 17.2%    | 3.8%    | 8.5%  |
| Total         | Count             | 29                | 53       | 82      |       |
|               | % within Kelompok | 100.0%            | 100.0%   | 100.0%  |       |

### JK \* Kelompok

#### Crosstab

|    |           |                   | Kelompok |         | Total  |
|----|-----------|-------------------|----------|---------|--------|
|    |           |                   | Kasus    | Kontrol |        |
| JK | Laki-Laki | Count             | 21       | 28      | 49     |
|    |           | % within Kelompok | 72.4%    | 52.8%   | 59.8%  |
|    | Perempuan | Count             | 8        | 25      | 33     |
|    |           | % within Kelompok | 27.6%    | 47.2%   | 40.2%  |
|    | Total     | Count             | 29       | 53      | 82     |
|    |           | % within Kelompok | 100.0%   | 100.0%  | 100.0% |

**Lampiran.** Distribusi Kadar NRAMP 1 pada Pasien TB dengan Kelainan Okular dan tanpa Kelainan Okular

### Case Processing Summary

|              |         | Valid |         | Cases Missing |         | Total |         |
|--------------|---------|-------|---------|---------------|---------|-------|---------|
| Kelompok     |         | N     | Percent | N             | Percent | N     | Percent |
| Kadar_NRAMP1 | Kasus   | 29    | 100.0%  | 0             | 0.0%    | 29    | 100.0%  |
|              | Kontrol | 53    | 100.0%  | 0             | 0.0%    | 53    | 100.0%  |

### Descriptives

| Kelompok     |         | Statistic                        |             | Std. Error  |
|--------------|---------|----------------------------------|-------------|-------------|
| Kadar_NRAMP1 | Kasus   | Mean                             | 138.8717540 | 4.934901277 |
|              |         | 95% Confidence Interval for Mean | Lower Bound | 128.7630670 |
|              |         |                                  | Upper Bound | 148.9804410 |
|              |         | 5% Trimmed Mean                  | 137.4392085 |             |
|              |         | Median                           | 123.1431145 |             |
|              |         | Variance                         | 706.244     |             |
|              |         | Std. Deviation                   | 26.57525669 |             |
|              |         | Minimum                          | 110.205921  |             |
|              |         | Maximum                          | 194.767247  |             |
|              |         | Range                            | 84.561325   |             |
|              |         | Interquartile Range              | 46.834122   |             |
|              |         | Skewness                         | .721        | .434        |
|              |         | Kurtosis                         | -.964       | .845        |
|              | Kontrol | Mean                             | 186.7322819 | 6.481097911 |
|              |         | 95% Confidence Interval for Mean | Lower Bound | 173.7270075 |
|              |         |                                  | Upper Bound | 199.7375564 |
|              |         | 5% Trimmed Mean                  | 178.2105118 |             |
|              |         | Median                           | 173.6986899 |             |
|              |         | Variance                         | 2226.245    |             |
|              |         | Std. Deviation                   | 47.18310500 |             |
|              |         | Minimum                          | 159.643098  |             |
|              |         | Maximum                          | 426.222115  |             |
|              |         | Range                            | 266.579017  |             |
|              |         | Interquartile Range              | 16.098497   |             |
|              |         | Skewness                         | 4.023       | .327        |
|              |         | Kurtosis                         | 17.310      | .644        |

### Tests of Normality

|               | Kelompok | Kolmogorov-Smirnov <sup>a</sup> |    |      | Shapiro-Wilk |    |      |
|---------------|----------|---------------------------------|----|------|--------------|----|------|
|               |          | Statistic                       | df | Sig. | Statistic    | df | Sig. |
| Kadar_NRAM P1 | Kasus    | .240                            | 29 | .000 | .854         | 29 | .001 |
|               | Kontrol  | .318                            | 53 | .000 | .481         | 53 | .000 |

a. Lilliefors Significance Correction

### Ranks

|               | Kelompok | N  | Mean Rank | Sum of Ranks |
|---------------|----------|----|-----------|--------------|
| Kadar_NRAM P1 | Kasus    | 29 | 22.19     | 643.50       |
|               | Kontrol  | 53 | 52.07     | 2759.50      |
|               | Total    | 82 |           |              |

### Test Statistics<sup>a</sup>

|                             |      |                         |  | Kadar_NRAM P1     |
|-----------------------------|------|-------------------------|--|-------------------|
| Mann-Whitney U              |      |                         |  | 208.500           |
| Wilcoxon W                  |      |                         |  | 643.500           |
| Z                           |      |                         |  | -5.432            |
| Asymp. Sig. (2-tailed)      |      |                         |  | .000              |
| Monte Carlo Sig. (2-tailed) | Sig. | 95% Confidence Interval |  | .000 <sup>b</sup> |
|                             |      | Lower Bound             |  | .000              |
|                             |      | Upper Bound             |  | .000              |
| Monte Carlo Sig. (1-tailed) | Sig. | 95% Confidence Interval |  | .000 <sup>b</sup> |
|                             |      | Lower Bound             |  | .000              |
|                             |      | Upper Bound             |  | .000              |

a. Grouping Variable: Kelompok

b. Based on 10000 sampled tables with starting seed 926214481.

**Lampiran.** Distribusi Ekspresi Gen NRAMP 1 pada Pasien TB dengan Kelainan Okular dan tanpa Kelainan Okular

| Case Processing Summary |          |       |         |               |         |       |         |
|-------------------------|----------|-------|---------|---------------|---------|-------|---------|
|                         | Kelompok | Valid |         | Cases Missing |         | Total |         |
|                         |          | N     | Percent | N             | Percent | N     | Percent |
| Ekspresi_NRAMP1         | Kasus    | 29    | 100.0%  | 0             | 0.0%    | 29    | 100.0%  |
|                         | Kontrol  | 53    | 100.0%  | 0             | 0.0%    | 53    | 100.0%  |

| Descriptives    |         |                                  |             |  |            |            |
|-----------------|---------|----------------------------------|-------------|--|------------|------------|
| Kelompok        |         |                                  |             |  | Statistic  | Std. Error |
| Ekspresi_NRAMP1 | Kasus   | Mean                             |             |  | .6050331   | .03504651  |
|                 |         | 95% Confidence Interval for Mean | Lower Bound |  | .5332436   |            |
|                 |         |                                  | Upper Bound |  | .6768226   |            |
|                 |         | 5% Trimmed Mean                  |             |  | .6023536   |            |
|                 |         | Median                           |             |  | .5885500   |            |
|                 |         | Variance                         |             |  | .036       |            |
|                 |         | Std. Deviation                   |             |  | .18873123  |            |
|                 |         | Minimum                          |             |  | .18051     |            |
|                 |         | Maximum                          |             |  | 1.06757    |            |
|                 |         | Range                            |             |  | .88706     |            |
|                 |         | Interquartile Range              |             |  | .25115     |            |
|                 |         | Skewness                         |             |  | .338       | .434       |
|                 |         | Kurtosis                         |             |  | .467       | .845       |
|                 | Kontrol | Mean                             |             |  | 1.4242447  | .17345971  |
|                 |         | 95% Confidence Interval for Mean | Lower Bound |  | 1.0761723  |            |
|                 |         |                                  | Upper Bound |  | 1.7723171  |            |
|                 |         | 5% Trimmed Mean                  |             |  | 1.2672392  |            |
|                 |         | Median                           |             |  | 1.2939000  |            |
|                 |         | Variance                         |             |  | 1.595      |            |
|                 |         | Std. Deviation                   |             |  | 1.26280574 |            |
|                 |         | Minimum                          |             |  | .15937     |            |
|                 |         | Maximum                          |             |  | 9.30687    |            |
|                 |         | Range                            |             |  | 9.14750    |            |
|                 |         | Interquartile Range              |             |  | .80782     |            |
|                 |         | Skewness                         |             |  | 4.851      | .327       |
|                 |         | Kurtosis                         |             |  | 29.795     | .644       |

### Tests of Normality

|                 | Kelompok | Kolmogorov-Smirnov <sup>a</sup> |    |                   | Shapiro-Wilk |    |      |
|-----------------|----------|---------------------------------|----|-------------------|--------------|----|------|
|                 |          | Statistic                       | df | Sig.              | Statistic    | df | Sig. |
| Ekspresi_NRAMP1 | Kasus    | .098                            | 29 | .200 <sup>*</sup> | .978         | 29 | .798 |
|                 | Kontrol  | .215                            | 53 | .000              | .556         | 53 | .000 |

\*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

### Ranks

|                 | Kelompok | N  | Mean Rank | Sum of Ranks |
|-----------------|----------|----|-----------|--------------|
| Ekspresi_NRAMP1 | Kasus    | 29 | 22.72     | 659.00       |
|                 | Kontrol  | 53 | 51.77     | 2744.00      |
|                 | Total    | 82 |           |              |

### Test Statistics<sup>a</sup>

|                        | Ekspresi_NR<br>AMP1 |
|------------------------|---------------------|
| Mann-Whitney U         | 224.000             |
| Wilcoxon W             | 659.000             |
| Z                      | -5.281              |
| Asymp. Sig. (2-tailed) | .000                |

a. Grouping Variable: Kelompok





**FORMULIR PERSETUJUAN SETELAH PENJELASAN (PSP)**  
**(INFORMED CONSENT)**

Template

Selamat pagi Bapak / Ibu /Saudara(i), saya **Ahmad Ashraf Amalius**, bermaksud untuk melakukan penelitian

Tujuan penelitian ini adalah untuk mengetahui ada tidaknya gejala-gejala gangguan lain pada mata dan fungsi penglihatan yang diakibatkan oleh adanya penyakit infeksi dan atau inflamasi pada mata yang Bapak/Ibu alami. Adapun manfaat penelitian ini adalah apabila terdeteksi maka dapat dilakukan pemeriksaan lanjutan dan juga pemberian terapi awal agar dapat mencegah peningkatan keparahan penyakit yang dapat mengganggu penglihatan.

Pada penelitian ini akan dibagi menjadi 2 kelompok, yaitu kelompok penderita Tuberkulosis ocular dan kelompok control.Kedua kelompok akan menjalani pemeriksaan yang sama yakni pemeriksaan oftalmologi dasar dan pemeriksaan oftalmologi tambahan. Pada pemeriksaan oftalmologi dasar akan diperiksa ketajaman penglihatan menggunakan Snellen chart dan dilakukan pemeriksaan imuniasi oblik menggunakan senter / penlight dan juga slitlamp. Setelah itu Bapak/Ibu akan dilakukan pemeriksaan oftalmologi tambahan berupa pemeriksaan funduskopi dan pemeriksaan segmen posterior lainnya berupa OCT (Optical Coherence Tomography).

Partisipan akan dibagi berdasarkan ada tidaknya penyakit tuberculosis okular yang di derita sehingga menjadi kelompok partisipan dengan tuberculosis dan tanpa tuberculosis.

Setiap partisipan dari kedua kelompok kemudian akan dilakukan pemeriksaan / pengambilan sampel darah sebanyak kurang lebih 3 cc dari darah balik (vena) di daerah lipatan siku (antara lengan atas dan lengan bawah), pada salah satu tangan. Pengambilan sampel darah ini dilakukan dengan prinsip sterilitas dan higienitas sehingga mencegah terjadinya hal-hal yang tidak diinginkan. Adapun pengambilan sampel darah ini mungkin akan sedikit terasa sakit pada orang-orang tertentu namun secara umum dapat di abaikan. Pengambilan sampel darah ini hanya dilakukan sekali saja. Efek samping lain yang bisa timbul akibat pengambilan sampel darah adalah kejadian hematoma (pembengkakan ringan) pada daerah bekas suntikan. Namun, efek tersebut dapat berangsur-angsur menghilang dalam beberapa hari dan dapat pula di bantu penyerapannya dengan pemberian obat berupa salep / krim / gel.

Partisipan yang bersedia untuk dilakukan penginputan data, pemeriksaan oftalmologi dan pengambilan sampel darah akan dimasukkan sebagai kriteria inklusi, sedangkan bagi partisipan yang mempunyai kelainan mata lain seperti glaucoma, lens induce uveitis serta infeksi dan inflamasi mata yang tidak terjadi pada tractus uvea maka dimasukkan sebagai kriteria eksklusi. Partisipan yang tidak dapat mengikuti pemeriksaan tersebut secara lengkap akan dianggap sebagai partisipan yang mengundurkan diri. Adapun keikutsertaan Bapak/Ibu pada penelitian ini adalah bersifat sukarela tanpa paksaan sedikitpun sehingga Bapak / Ibu dapat mengundurkan diri kapan saja tanpa mengurangi hak anda untuk mendapatkan pelayanan kesehatan. Jika Bapak/Ibu bersedia sebagai partisipan maka kami harapkan Bapak/Ibu dapat mengikuti semua prosedur pemeriksaan sampai selesai.

Adapun penelitian ini dibiayai secara mandiri oleh peneliti utama. Aspek pembiayaan pada penelitian ini meliputi biaya pemeriksaan darah, pemberian obat tetes mata topikal bila diperlukan dan penanganan efek samping yang terjadi. Jika terjadi hal-hal yang tidak diinginkan maka peneliti akan memberikan biaya ganti rugi kepada Bapak / Ibu sesuai dengan resiko yang terjadi. Namun, semoga hal ini tidak terjadi atau

diminimalisir karena peneliti akan melakukan segala prosedur penelitian sesuai dengan standar pelayanan medis yang berlaku.

Bagi Bapak/Ibu yang bersedia sebagai partisipan akan diberikan kompensasi pada saat pemeriksaan berupa snack (kue dan minuman) ataupun nasi kotak apabila waktu pemeriksaan yang memanjang karena antrian dari pemeriksaan lain sebelumnya. Segala data yang kami peroleh dari Bapak/Ibu pada penelitian ini akan kami jaga kerahasiaannya.

Jika ada hal yang ingin ditanyakan mengenai penelitian ini dapat menghubungi penelitian dengan alamat dan nomor kontak di bawah ini atau menghubungi Komisi etik Penelitian Kesehatan Fakultas Kedokteran Universitas Hasanuddin An. Ibu Rahayu Iriani no HP. 081343825297 atau dr. Agussalim Bukhari, M.Med, Ph.D, Sp.GK (K) No. HP. 081225704670 Alamat: Jl. Perintis Kemerdekaan KM 10 Tamalanrea 90245, Makassar.

Identitas Peneliti

Nama : Ahmad Ashraf Amalius

Alamat : Jalan Raya Pendidikan Kompleks UNM Blok G 3 /36 Makassar

No Hp : 081242158001

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI  
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN



KOMITE ETIK PENELITIAN KESEHATAN  
RSPTN UNIVERSITAS HASANUDDIN



RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR

Sekretariat : Lantai 2 Gedung Laboratorium Terpadu

JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.

Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

---

**FORMULIR PERSETUJUAN SETELAH PENJELASAN**

Saya yang bertandatangan di bawah ini :

Nama : .....  
Umur : .....  
Masa Kerja : .....  
Satuan : .....  
Alamat : .....  
.....

setelah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan, manfaat, dan apa yang akan dilakukan pada penelitian ini, menyatakan setuju untuk ikut dalam penelitian ini secara sukarela tanpa paksaan.

Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini. Saya berhak bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya juga mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini, akan ditanggung oleh peneliti. Saya percaya bahwa keamanan dan kerahasiaan data penelitian akan terjamin dan saya dengan ini menyetujui semua data saya yang dihasilkan pada penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan.

Dengan membubuhkan tandatangan saya di bawah ini, saya menegaskan keikutsertaan saya secara sukarela dalam studi penelitian ini.

|           | <b>Nama</b> | <b>Tanda tangan</b> | <b>Tgl/Bln/Thn</b> |
|-----------|-------------|---------------------|--------------------|
| Responden | .....       | .....               | .....              |
| /Wali     |             |                     |                    |
| Saksi     | .....       | .....               | .....              |

(Tanda Tangan Saksi diperlukan hanya jika Partisipan tidak dapat memberikan consent/persetujuan sehingga menggunakan wali yang sah secara hukum, yaitu untuk partisipan berikut:

1. Berusia di bawah 18 tahun
2. Usia lanjut
3. Gangguan mental
4. Pasien tidak sadar
5. Dan lain-lain kondisi yang tidak memungkinkan memberikan persetujuan

**Penanggung Jawab Penelitian :**

Nama : Ahmad Ashraf Amalius

Alamat : Kompleks UNM G3/36 Makassar

Tlp : 081242158001

**Penanggung Jawab Medis :**

Nama : Ahmad Ashraf Amalius

Alamat : Kompleks UNM G 3/36 Makassar

Tlp : 081242158001

### **FORMULIR SUBYEK PENELITIAN**

**(Ekspresi Gen & Kadar Protein NRAMB1 Pada Penderita Tuberkulosis Okular)**

**Nomor :**

**Tanggal Pengambilan :**

**Nama subyek penelitian :**

**Umur :**

**Riwayat TB : Ya / Tidak (coret yang tidak sesuai)**

**Kelompok : TB / Non TB (coret yang tidak sesuai)**

| <b>PARAMETER</b> | <b>OCULUS DEXTER</b> | <b>OCULUS SINISTER</b> |
|------------------|----------------------|------------------------|
| <b>Visus</b>     |                      |                        |
| <b>Palpebra</b>  |                      |                        |

|                       |  |  |
|-----------------------|--|--|
| <b>Silia</b>          |  |  |
| <b>Konjungtiva</b>    |  |  |
| <b>Sklera</b>         |  |  |
| <b>Kornea</b>         |  |  |
| <b>BMD</b>            |  |  |
| <b>Iris</b>           |  |  |
| <b>Pupil</b>          |  |  |
| <b>Lensa</b>          |  |  |
| <b>Vitreous</b>       |  |  |
| <b>Nervus Optik</b>   |  |  |
| <b>Makula</b>         |  |  |
| <b>Retina Perifer</b> |  |  |

